Potent Ex Vivo Activity of Naphthoquine and Methylene Blue against Drug-Resistant Clinical Isolates of Plasmodium falciparum and Plasmodium vivax

被引:19
作者
Wirjanata, Grennady [1 ,2 ]
Sebayang, Boni F. [3 ]
Chalfein, Ferryanto [4 ]
Prayoga [4 ]
Handayuni, Irene [1 ,2 ]
Trianty, Leily [3 ]
Kenangalem, Enny [4 ,5 ]
Noviyanti, Rintis [3 ]
Campo, Brice [6 ]
Poespoprodjo, Jeanne Rini [4 ]
Moehrle, Joerg J. [6 ]
Price, Ric N. [1 ,2 ,7 ]
Marfurt, Jutta [1 ,2 ]
机构
[1] Menzies Sch Hlth Res, Global & Trop Hlth Div, Darwin, NT, Australia
[2] Charles Darwin Univ, Darwin, NT 0909, Australia
[3] Eijkman Inst Mol Biol, Jakarta, Indonesia
[4] Papuan Hlth & Community Dev Fdn PHCDF, Timika, Papua, Indonesia
[5] Dist Hlth Author, Timika, Papua, Indonesia
[6] MMV, Geneva, Switzerland
[7] Univ Oxford, Ctr Trop Med & Global Hlth, Nuffield Dept Clin Med, Oxford, England
基金
英国惠康基金; 英国医学研究理事会; 瑞士国家科学基金会;
关键词
ARTEMISININ-NAPHTHOQUINE; DIHYDROARTEMISININ-PIPERAQUINE; GLUTATHIONE-REDUCTASE; ANTIMALARIAL-DRUGS; MALARIA; CHLOROQUINE; COMBINATION; SAFETY; CHILDREN; PAPUA;
D O I
10.1128/AAC.00874-15
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The 4-aminoquinoline naphthoquine (NQ) and the thiazine dye methylene blue (MB) have potent in vitro efficacies against Plasmodium falciparum, but susceptibility data for P. vivax are limited. The species- and stage-specific ex vivo activities of NQ and MB were assessed using a modified schizont maturation assay on clinical field isolates from Papua, Indonesia, where multidrug-resistant P. falciparum and P. vivax are prevalent. Both compounds were highly active against P. falciparum (median [range] 50% inhibitory concentration [IC50]: NQ, 8.0 nM [2.6 to 71.8 nM]; and MB, 1.6 nM [0.2 to 7.0 nM]) and P. vivax (NQ, 7.8 nM [1.5 to 34.2 nM]; and MB, 1.2 nM [0.4 to 4.3 nM]). Stage-specific drug susceptibility assays revealed significantly greater IC(50)s in parasites exposed at the trophozoite stage than at the ring stage for NQ in P. falciparum (26.5 versus 5.1 nM, P = 0.021) and P. vivax (341.6 versus 6.5 nM, P = 0.021) and for MB in P. vivax (10.1 versus 1.6 nM, P = 0.010). The excellent ex vivo activities of NQ and MB against both P. falciparum and P. vivax highlight their potential utility for the treatment of multidrug-resistant malaria in areas where both species are endemic.
引用
收藏
页码:6117 / 6124
页数:8
相关论文
共 50 条
  • [31] Fighting drug-resistant Plasmodium falciparum: the challenge of artemisinin resistance
    Wongsrichanalai, C.
    Sibley, C. H.
    CLINICAL MICROBIOLOGY AND INFECTION, 2013, 19 (10) : 908 - 916
  • [32] Ex vivo Sensitivity Profile of Plasmodium falciparum Clinical Isolates to a Panel of Antimalarial Drugs in Ghana 13 Years After National Policy Change
    Ofori, Michael Fokuo
    Kploanyi, Emma E.
    Mensah, Benedicta A.
    Dickson, Emmanuel K.
    Kyei-Baafour, Eric
    Gyabaa, Sampson
    Tetteh, Mary
    Koram, Kwadwo A.
    Abuaku, Benjamin K.
    Ghansah, Anita
    INFECTION AND DRUG RESISTANCE, 2021, 14 : 267 - 276
  • [33] Nationwide spatiotemporal drug resistance genetic profiling from over three decades in Indian Plasmodium falciparum and Plasmodium vivax isolates
    Foko, Loick Kojom P.
    Narang, Geetika
    Jakhan, Jahnvi
    Tamang, Suman
    Moun, Amit
    Singh, Vineeta
    MALARIA JOURNAL, 2023, 22 (01)
  • [34] Plasmodium falciparum Drug-Resistant Haplotypes and Population Structure in Postearthquake Haiti, 2010
    Morton, Lindsay Carol
    Huber, Curtis
    Okoth, Sheila Akinyi
    Griffing, Sean
    Lucchi, Naomi
    Ljolje, Dragan
    Boncy, Jacques
    Oscar, Roland
    Townes, David
    McMorrow, Meredith
    Chang, Michelle A.
    Udhayakumar, Venkatachalam
    Barnwell, John W.
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2016, 95 (04) : 811 - 816
  • [35] Ex Vivo Drug Susceptibility Testing and Molecular Profiling of Clinical Plasmodium falciparum Isolates from Cambodia from 2008 to 2013 Suggest Emerging Piperaquine Resistance
    Chaorattanakawee, Suwanna
    Saunders, David L.
    Sea, Darapiseth
    Chanarat, Nitima
    Yingyuen, Kritsanai
    Sundrakes, Siratchana
    Saingam, Piyaporn
    Buathong, Nillawan
    Sriwichai, Sabaithip
    Charm, Soklyda
    Se, Youry
    Yom, You
    Heng, Thay Kheng
    Kong, Nareth
    Kuntawunginn, Worachet
    Tangthongchaiwiriya, Kuntida
    Jacob, Christopher
    Takala-Harrison, Shannon
    Plowe, Christopher
    Lin, Jessica T.
    Chuor, Char Meng
    Prom, Satharath
    Tyner, Stuart D.
    Gosi, Panita
    Teja-Isavadharm, Paktiya
    Lon, Chanthap
    Lanteria, Charlotte A.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (08) : 4631 - 4643
  • [36] Differential ex vivo susceptibility of Plasmodium malariae and Plasmodium falciparum clinical isolates from Ghana and Mali to current and lead discovery candidate antimalarial drugs
    Soulama, Alamissa
    Sogore, Fanta
    Ansah, Felix
    Diakite, Ousmaila
    Chirawurah, Jersley D.
    Maiga, Fatoumata O.
    Maiga, Mohamed
    Danwonno, Harry A.
    Campo, Brice
    Djimde, Abdoulaye A.
    Awandare, Gordon A.
    Amenga-Etego, Lucas N.
    Dembele, Laurent
    Aniweh, Yaw
    MICROBIOLOGY SPECTRUM, 2025, 13 (04)
  • [37] Molecular Surveillance and Ex Vivo Drug Susceptibilities of Plasmodium vivax Isolates From the China-Myanmar Border
    Zeng, Weilin
    Zhao, Hui
    Zhao, Wei
    Yang, Qi
    Li, Xinxin
    Li, Xiaosong
    Duan, Mengxi
    Wang, Xun
    Li, Cuiying
    Xiang, Zheng
    Chen, Xi
    Cui, Liwang
    Yang, Zhaoqing
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2021, 11
  • [38] Ex vivo susceptibility and genotyping of Plasmodium falciparum isolates from Pikine, Senegal
    Mbaye, Aminata
    Gaye, Amy
    Dieye, Baba
    Ndiaye, Yaye D.
    Bei, Amy K.
    Affara, Muna
    Deme, Awa B.
    Yade, Mamadou S.
    Diongue, Khadim
    Ndiaye, Ibrahima M.
    Ndiaye, Tolla
    Sy, Mouhamed
    Sy, Ngayo
    Koita, Ousmane
    Krogstad, Donald J.
    Volkman, Sarah
    Nwakanma, Davis
    Ndiaye, Daouda
    MALARIA JOURNAL, 2017, 16
  • [39] Molecular epidemiology of drug-resistant Plasmodium falciparum in Benguela province, Angola
    Vincent Foumane Ngane
    Joseph Allico Djaman
    Cécile Culeux
    Nathalie Piette
    Pierre Carnevale
    Patrick Besnard
    Filomeno Fortes
    Leonardo K Basco
    Rachida Tahar
    Malaria Journal, 14
  • [40] Ex vivo activity of the ACT new components pyronaridine and piperaquine in comparison with conventional ACT drugs against isolates of Plasmodium falciparum
    Aurélie Pascual
    Philippe Parola
    Françoise Benoit-Vical
    Fabrice Simon
    Denis Malvy
    Stéphane Picot
    Pascal Delaunay
    Didier Basset
    Danièle Maubon
    Bernard Faugère
    Guillaume Ménard
    Nathalie Bourgeois
    Claude Oeuvray
    Eric Didillon
    Christophe Rogier
    Bruno Pradines
    Malaria Journal, 11